清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Can Bisphosphonate Therapy Reduce Overall Mortality in Patients With Osteoporosis? A Meta-analysis of Randomized Controlled Trials

医学 荟萃分析 随机对照试验 安慰剂 梅德林 科克伦图书馆 子群分析 双膦酸盐 骨质疏松症 内科学 系统回顾 临床试验 物理疗法 替代医学 病理 政治学 法学
作者
Zhibin Lan,Xue Lin,Di Xue,Yang Yang,Muhammad Saad,Qunhua Jin
出处
期刊:Clinical Orthopaedics and Related Research [Ovid Technologies (Wolters Kluwer)]
标识
DOI:10.1097/corr.0000000000003204
摘要

Background For patients with osteoporosis, bisphosphonate therapy can reduce the risk of fractures, but its effect on reducing mortality remains unclear. Previous studies on this topic have produced conflicting results and generally have been too small to definitively answer the question of whether bisphosphonate therapy reduces mortality. Therefore, a meta-analysis may help us arrive at a more conclusive answer. Questions/purposes In a large meta-analysis of placebo-controlled randomized controlled trials (RCTs), we asked: (1) Does bisphosphonate use reduce mortality? (2) Is there a subgroup effect based on whether different bisphosphonate drugs were used (zoledronate, alendronate, risedronate, and ibandronate), different geographic regions where the study took place (Europe, the Americas, and Asia), whether the study was limited to postmenopausal female patients, or whether the trials lasted 3 years or longer? Methods We conducted a systematic review using multiple databases, including Embase, Web of Science, Medline (via PubMed), Cochrane Library, and ClinicalTrials.gov, with each database searched up to November 20, 2023 (which also was the date of our last search), following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We included randomized, placebo-controlled clinical trials with participants diagnosed with osteoporosis and receiving bisphosphonate treatment. We excluded papers posted to preprint servers, other unpublished work, conference abstracts, and papers that were registered on ClinicalTrials.gov but were not yet published. We collected 2263 records. After excluding records due to study type, study content not meeting the inclusion criteria, and duplicates, our meta-analysis included 47 placebo-controlled RCTs involving 59,437 participants. Data extraction, quality assessment, and statistical analyses were performed. The evaluation of randomized trials for potential bias was conducted using the revised Cochrane Risk of Bias tool. This assessment encompassed factors such as sequence generation, allocation concealment, subject blinding, outcome assessor blinding, incomplete outcome data, and reporting bias. Some studies did not provide explicit details regarding random sequence generation, leading to a high risk of selection bias. A few studies, due to their open-label nature, were unable to achieve double-blind conditions for both the subjects and the researchers, resulting in intermediate performance bias. Nevertheless, the overall study quality was high. Due to the low heterogeneity among the studies, as evidenced by the low statistical heterogeneity (that is, a low I 2 statistic), we opted for a fixed-effects model, indicating that the effect size is consistent across the studies. In such cases, the fixed-effects model can provide more precise estimates. According to the results of the funnel plot, we did not find evidence of publication bias. Results The use of bisphosphonates did not reduce the overall risk of mortality in patients with osteoporosis (risk ratio 0.95 [95% CI 0.88 to 1.03]). Subgroup analyses involving different bisphosphonate drugs (zoledronate, alendronate, risedronate, and ibandronate), regions (Europe, the Americas, and Asia), diverse populations (postmenopausal female patients and other patients), and trials lasting 3 years or longer revealed no associations with reduced overall mortality. Conclusion Based on our comprehensive meta-analysis, there is high-quality evidence suggesting that bisphosphonate therapy for patients with osteoporosis does not reduce the overall risk of mortality despite its effectiveness in reducing the risk of fractures. The primary consideration for prescribing bisphosphonates to individuals with osteoporosis should continue to be centered on reducing fracture risk, aligning with clinical guidelines. Long-term studies are needed to investigate potential effects on mortality during extended treatment periods. Level of Evidence Level I, therapeutic study.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
曾经不言完成签到 ,获得积分10
17秒前
鞋子完成签到,获得积分10
26秒前
Echo完成签到,获得积分10
46秒前
梅啦啦完成签到 ,获得积分10
52秒前
h0jian09完成签到,获得积分10
1分钟前
宇文雨文完成签到 ,获得积分10
1分钟前
Lavendar完成签到 ,获得积分10
1分钟前
apathetic完成签到,获得积分10
1分钟前
jfc完成签到 ,获得积分10
1分钟前
Alan完成签到 ,获得积分10
1分钟前
酸奶球完成签到 ,获得积分10
1分钟前
2分钟前
属实有点拉胯完成签到 ,获得积分10
2分钟前
加贝完成签到,获得积分10
2分钟前
lli发布了新的文献求助10
2分钟前
简单问儿完成签到 ,获得积分10
3分钟前
Casey完成签到 ,获得积分10
3分钟前
科研通AI2S应助jlwang采纳,获得10
3分钟前
123完成签到 ,获得积分10
3分钟前
风秋杨完成签到 ,获得积分10
3分钟前
EVEN完成签到 ,获得积分10
3分钟前
tracyzhang完成签到 ,获得积分10
3分钟前
爱静静完成签到,获得积分0
4分钟前
数乱了梨花完成签到 ,获得积分10
4分钟前
Nan发布了新的文献求助30
4分钟前
qyang完成签到 ,获得积分10
4分钟前
小强完成签到 ,获得积分10
4分钟前
john发布了新的文献求助10
4分钟前
嗡嗡完成签到,获得积分10
4分钟前
重重重飞完成签到 ,获得积分10
4分钟前
诺亚方舟哇哈哈完成签到 ,获得积分0
4分钟前
emma完成签到 ,获得积分10
4分钟前
科研小狗完成签到 ,获得积分10
4分钟前
怡然白竹完成签到 ,获得积分10
5分钟前
房天川完成签到 ,获得积分10
5分钟前
digger2023完成签到 ,获得积分10
5分钟前
iberis完成签到 ,获得积分10
5分钟前
herpes完成签到 ,获得积分0
6分钟前
john完成签到,获得积分10
6分钟前
井小浩完成签到 ,获得积分10
6分钟前
高分求助中
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Дружба 友好报 (1957-1958) 1000
The Data Economy: Tools and Applications 1000
A Dissection Guide & Atlas to the Rabbit 600
Mantiden - Faszinierende Lauerjäger – Buch gebraucht kaufen 500
PraxisRatgeber Mantiden., faszinierende Lauerjäger. – Buch gebraucht kaufe 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3104034
求助须知:如何正确求助?哪些是违规求助? 2755262
关于积分的说明 7631487
捐赠科研通 2408562
什么是DOI,文献DOI怎么找? 1277908
科研通“疑难数据库(出版商)”最低求助积分说明 617236
版权声明 599199